Clinical trialsCompany release
Remix's oral MYB degrader REM-422 shows responses in 4 of 7 biomarker-positive ACC patients
🇺🇸 Passage BIO, Inc. (PASG) · Thu 19 Nov 2026
Late-breaking Phase 1 data at 24 mg, the recommended Phase 2 dose, show a 57% response rate in biomarker-positive adenoid cystic carcinoma, with no dose-limiting toxicities reported.
Remix Therapeutics presented updated Phase 1 results for REM-422 on 19 November 2026 as a late-breaking abstract at the EORTC-NCI-AACR Symposium. REM-422 is an oral MYB mRNA degrader. The data come from the Phase 1 part of the ARIA Phase 1/2 study in recurrent or metastatic adenoid cystic carcinoma (ACC).
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Passage BIO, Inc. ↗
Article written by VigiEye from the official source (Passage BIO, Inc.). Claims are the company's own. AI-assisted; check the source before acting.
More Clinical trials
All →
Evaxion refocuses on cancer vaccines as EVX-04 heads toward phase 1 filing
Evaxion · Thu 19 Nov 2026
Teleflex recalls PICC kits and spring-wire guides over coating detachment risk, Health Canada reports
🇨🇦 Health Canada · Wed 18 Nov 2026
Health Canada: Raz Design recalls shower commode chairs over seats that can break
🇨🇦 Health Canada · Wed 18 Nov 2026
Summit starts Phase III HARMONi-10 of ivonescimab against durvalumab in Stage III NSCLC
🇺🇸 Summit Therapeutics Inc. (SMMT) · Wed 18 Nov 2026
NeOnc deck reports Phase 2a intranasal NEO100 results in recurrent IDH1-mutant glioma
🇺🇸 Neonc Technologies Holdings, Inc. (NTHI) · Wed 18 Nov 2026
Lantern Pharma opens first TNBC trial site, starts HARMONIC Part 2 in Taiwan; CEO resigns
🇺🇸 Lantern Pharma Inc. (LTRN) · Wed 18 Nov 2026